论文部分内容阅读
肾癌是目前泌尿系统常见的恶性肿瘤之一,发病率占全身恶性肿瘤的3%,而肾透明细胞癌占肾癌的70%～80%。针对晚期或转移性肾癌的抗肿瘤血管生成的分子靶向治疗已取得令人满意的疗效,但肾癌生物学行为极为复杂多变,目前仍缺乏对肾癌患者预后以及靶向药物治疗效果进行评价的有效分子标志物。本文综述了与肾透明细胞癌预后密切相关的肿瘤分子标志物的研究进展。
Renal cancer is one of the common malignant tumors of the urinary system, the incidence rate of 3% of systemic malignant tumors, and renal clear cell carcinoma of renal cell carcinoma accounted for 70% to 80%. Targeted molecular targeted therapy of anti-angiogenesis in advanced or metastatic renal cell carcinoma has achieved satisfactory efficacy, but the biological behavior of renal cell carcinoma is extremely complex and changeable, and the prognosis of patients with renal cell carcinoma and the effect of targeted drug therapy are still lacking An effective molecular marker for evaluation. This review summarizes the progress of tumor molecular markers closely related to the prognosis of renal clear cell carcinoma.